|Bid||94.45 x 1000|
|Ask||94.55 x 800|
|Day's Range||93.51 - 98.61|
|52 Week Range||3.54 - 111.77|
|Beta (5Y Monthly)||1.49|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||115.00|
The government is deciding who the winners among individual companies are and giving losers another chance. It feels strange and new, even if what it’s spending is peanuts compared with the dollars it’s tossing around elsewhere.
Since I last wrote about Delta (NYSE:DAL) and DAL stock in late May, it rose from around $20 to roughly $28 per share. I rated it as a buy then, which was an easy pick given the environment and Delta's liquidity levels at that time.Source: Markus Mainka / Shutterstock.com Investors who worry that any appreciation has lost steam shouldn't worry too much. Delta shares will continue to rise although second-quarter earnings will be bleak. Long-term investors should continue to view the company as one with positive momentum heading into, and out of, the novel coronavirus pandemic. DAL Stock Q2 Earnings Beat?It will be no surprise when Delta reports a year-over-year earnings decline. Inventors will be interested to know that the magnitude of that expected loss has been declining.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIn the previous month analysts revised the loss expectation to be roughly 18% lower than expected. Analysts expect Delta to post an EPS loss of $4.21. The company remains a buy-and-hold candidate in my eyes. The company has lots of liquidity to counterbalance ongoing cash burn even in the face of the recent outbreaks of Covid-19 cases. Analysts are currently bullish on DAL shares. Nine rate it as a buy, and seven a hold. None are rating it a sell. Analyst consensus is that shares are overweight. Their average price target is $36.31. So, from the current price there is room to appreciate. Investors should also expect that there is significant variation among those analysts' projections given the pandemic. Variation in that guidance ranges from a low of $21 to a high of $47. But the thrust of their predictions is positive. Delta Can Sustain ItselfDelta does have sufficient liquidity as a bulwark against a continued gutting of air traffic demand. However, operators must remain hyper-vigilant against outbreaks capable of inflicting further serious material losses in the extremely hard-hit airline sector. * The 7 Best Stocks to Invest in Right NowCarriers are constantly balancing positive news against the negative and adjusting. In light of this, United Airlines' (NASDAQ:UAL) warning about recent outbreaks dampening a rebound in flight traffic is worrisome. There is some degree of herd immunity and reports suggest that people have become less fearful of this virus as time passes. But airlines are in need of a vaccine. Airlines Really Need a VaccineAnd on that front there has been some positive news. Regeneron (NASDAQ:REGN) and Novavax (NASDAQ:NVAX) received $450 million and $1.6 billion from the federal government to fund vaccine trials and manufacturing. The $1.6 billion the federal government gave to Novavax will be used to fund clinical trials and for manufacturing. Novavax stated it will deliver 100 million doses of its vaccine in the U.S. by year end. The federal government awarded Regeneron the $450 million contract to manufacture thousands of doses of its Covid-19 treatment. Should Regeneron's experimental vaccine prove effective and gain regulatory approval, it will be distributed to the public free. Shares of Regeneron rose 3.5%, with Novavax's shares rising by 29%. Should Investors Sell DAL Stock?All of these factors affect Delta directly. But the takeaway here is that not much has changed: the pandemic situation is highly fluid. Delta is in good position financially to continue to stand tall against this challenge. The federal government is funding more new vaccine trials which we can all collectively hope turn out positive. The newest virus outbreaks are disheartening, but fundamentally DAL shares are still poised for a return. Despite whatever happens with Q2 earnings news, Delta should be fine. There is still plenty of room to make money with this stock. As of writing, Alex Sirois does not own any of the aforementioned stocks. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post Delta Still a Strong Pick Despite Uptick in Covid-19 Cases appeared first on InvestorPlace.
This month, the U.S. government awarded Novavax (NASDAQ: NVAX) more funding than any other company in the coronavirus vaccine race. Operation Warp Speed, the government's effort to help bring a vaccine to market by January, awarded the biotech company $1.6 billion. The move surprised the market, as Novavax wasn't on the government's list of five companies to potentially receive funding.
You can’t always get what you want, but if you try sometimes… You do get what you want?After initially being excluded from the U.S. government’s Operation Warp Speed (OWS) program, Novavax (NVAX) joined the list of companies eligible for federal support.On July 7, the vaccine specialist announced it will receive $1.6 billion from the federal government to support the development of its COVID-19 vaccine candidate, NVX-CoV2373. 5-star B.Riley FBR analyst Mayank Mamtani is impressed by the scale of the award itself, noting: "[T]his funding is the largest granted by OWS to date, correlating with the (1) robustness of preclinical data generated and (2) favorable readthrough from the unequivocally positive Phase 3 NanoFlu study earlier in the year. In comparison, OWS' previously granted $1.2 billion and $0.5 billion to AstraZeneca and Moderna (MRNA), respectively. Most encouraging, this enables OWS to have all platform approaches in its top 3 prioritized vaccine candidates, i.e., messenger RNA from MRNA, adenovirus viral vector approach from AZ, and protein-based approach from NVAX.”The inclusion provides a measure of vindication for Mamtani, who had previously argued the case for Novavax’s place in the program. The analyst believes the funds will now enable Novavax to proceed with a Phase 3 trial in 3Q and to achieve its goal of producing 100 million doses by the end of the year. Should all go as planned – the company expects to enroll 30,000 participants for the fall trial – Novavax could even apply for regulatory approval before the end of 2020.To this end, Mamtani reiterated a Buy rating on NVAX shares, along with a $106 price target. This suggests 10% upside potential from current levels. (To watch Mamtani’s track record, click here)Among Mamtani’s colleagues, the biotech has a Moderate Buy consensus rating, based on 3 Buys and 2 Holds. Following the recent gains, the $101.20 average price target implies shares could rise by a modest 3% from current levels. (See Novavax stock analysis on TipRanks)Overall, Novavax stock has been a Wall Street favorite in 2020, to say the least. The stock has appreciated by a barely believable 2,307% since the turn of the year.To find good ideas for biotech stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
The United States will potentially have tens of millions of doses of experimental COVID-19 vaccines available by this fall and hundreds of millions of doses by the beginning of 2021, a top health official said on Thursday. U.S. Department of Health and Human Services Secretary Alex Azar on Thursday said during an internet interview with The Hill that the early doses would be the result of government funding to scale up manufacturing ahead of the vaccines being approved by regulators. The government has provided billions of dollars for vaccines under development at Moderna, Johnson & Johnson , AstraZeneca and Novavax.
On Wednesday, Novavax (NASDAQ: NVAX) took a bit of a breather from its impressive run on the stock market year to date. The catalyst for this slump may have been the fact that Ladenburg Thalmann analyst Michael Higgins downgraded Novavax's stock from neutral to buy, pointing to valuation concerns. Largely thanks to its efforts to develop a vaccine for the SARS-CoV-2 virus that causes COVID-19, Novavax's shares are up by more than 2300% since the beginning of the year.
The U.S. topped 3 million coronavirus cases Wednesday after setting a new record of 60,000 daily cases in the previous day.
Dr. Fauci says he expects phase 3 vaccine trials to begin at the end of July. Yahoo Finance's Anjalee Khemlani joins the On the Move panel to discuss where vaccine trials stand.
The midcap drugmaker said Wednesday it would collaborate with the Mount Sinai Health System to test a drug derived from blood plasma taken from recovered Covid-19 patients.
With late-stage clinical development costs covered by the government's funds, Novavax is cleared for takeoff.
Novovax (NVAX) is evaluating a coronavirus vaccine candidate, NVX-CoV2373, in a phase I/II study. A pivotal study is due to start in the fourth quarter.
The stock market fell Tuesday, but is a sustained pullback in the offing. Tesla and EV rival Nio keeps moving early. Facebook is in focus after execs met with ad boycott organizers.
There are many pharmaceutical companies are pursuing a vaccine, and the market has already started rewarding some of them. For instance, Novavax (NASDAQ: NVAX) is up a startling 2,500% in 2020. Novavax is not the only winner, however.
China's Clover Biopharmaceuticals Inc has received $66 million in investment from the Coalition for Epidemic Preparedness Innovation (CEPI) to bolster the testing of a potential COVID-19 vaccine, the global epidemic response group said on Wednesday. Last month, Clover became the sixth Chinese developer of a potential COVID-19 vaccine to move into human trials by launching a study in Australia to test its vaccine with boosters. The foundation said the funding aims to help produce hundreds of millions of doses of the potential vaccine per year and if the early stage trials are successful, it expects to provide "significant" additional support.
Stocks to consider as biotech company Novavax gets $1.6 billion in federal aid for Covie-19 vaccine Continue reading...
The Trump administration began the process of formally withdrawing from the World Health Organization, making good on its vow to revoke support for the embattled agency.
U.S. stocks fell on Tuesday, adding to losses into the close, as investors took profits a day after the S&P 500 logged its longest streak of gains this year and as new U.S. coronavirus cases rose further. Large parts of the United States reported tens of thousands of new coronavirus infections. Mester said during an interview with CNBC that a resurgence in coronavirus cases across the country is making consumers more cautious, and more fiscal stimulus is needed to help the economy recover fully from the crisis.
Novavax stock rocketed Tuesday after the biotech company nabbed $1.6 billion in government funding for its coronavirus vaccine. Regeneron also inked a manufacturing deal for its drug.